{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:32:56Z","timestamp":1773423176651,"version":"3.50.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/bor.0000000000000023","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T04:40:15Z","timestamp":1389674415000},"page":"237-243","source":"Crossref","is-referenced-by-count":17,"title":["Advances in kinase inhibition"],"prefix":"10.1097","volume":"26","author":[{"given":"Massimo","family":"Gadina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/clpt.2011.278","article-title":"Biologics-based therapy for the treatment of rheumatoid arthritis.","volume":"91","author":"Scott","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R2-21-20210128","first-page":"5","article-title":"Kinase inhibitors in the treatment of immune-mediated disease.","volume":"4","author":"Kontzias","year":"2012","journal-title":"F1 Med Rep"},{"key":"R3-21-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses.","volume":"28","author":"OShea","year":"2008","journal-title":"Immunity"},{"key":"R4-21-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbrc.2012.10.024","article-title":"Cellular regulation by protein phosphorylation.","volume":"430","author":"Fischer","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"R5-21-20210128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"R6-21-20210128","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2009.119479","article-title":"Go upstream, young man: lessons learned from the p38 saga.","volume":"69","author":"Hammaker","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R7-21-20210128","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/ket225","article-title":"Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.","volume":"52","author":"Nijjar","year":"2013","journal-title":"Rheumatology"},{"key":"R8-21-20210128","first-page":"1","article-title":"Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.","volume":"0","author":"Salgado","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R9-21-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions.","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 2","key":"R10-21-20210128","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases.","volume":"72","author":"OShea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R11-21-20210128","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"R12-21-20210128","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R13-21-20210128","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"R15-21-20210128","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"R16-21-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2207","article-title":"Signaling via the kinase p38alpha programs dendritic cells to drive TH17 differentiation and autoimmune inflammation.","volume":"13","author":"Huang","year":"2012","journal-title":"Nat Immunol"},{"key":"R17-21-20210128","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.","volume":"191","author":"Sohn","year":"2013","journal-title":"J Immunol"},{"key":"R18-21-20210128","first-page":"317","article-title":"The efficacy of ustekinumab in psoriasis.","volume":"12","author":"Famenini","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"R19-21-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11894-012-0311-3","article-title":"Novel targets for inflammatory bowel disease therapeutics.","volume":"15","author":"Lowenberg","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"R20-21-20210128","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"key":"R21-21-20210128","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10875-012-9849-y","article-title":"Tofacitinib a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.","volume":"33","author":"Yokoyama","year":"2013","journal-title":"J Clin Immunol"},{"key":"R22-21-20210128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.bmcl.2013.02.012","article-title":"Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.","volume":"23","author":"Lynch","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"R23-21-20210128","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.bmcl.2013.03.015","article-title":"Discovery of a series of novel 5H-pyrrolo2,3-bpyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.","volume":"23","author":"Jaime-Figueroa","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"R24-21-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/jm301646k","article-title":"3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs. JAK1 selective inhibitor and evaluation in cellular and in vivo models.","volume":"56","author":"Soth","year":"2013","journal-title":"J Med Chem"},{"key":"R25-21-20210128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bmcl.2012.11.108","article-title":"Design and synthesis of tricyclic cores for kinase inhibition.","volume":"23","author":"Van Epps","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"R26-21-20210128","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1016\/j.bmcl.2013.08.082","article-title":"Design and evaluation of novel 8-oxo-pyridopyrimidine Jak12 inhibitors.","volume":"23","author":"Labadie","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"R27-21-20210128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2013.03.070","article-title":"Lead identification of novel and selective TYK2 inhibitors.","volume":"67","author":"Liang","year":"2013","journal-title":"Eur J Med Chem"},{"key":"R29-21-20210128","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1021\/jm4004895","article-title":"Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.","volume":"56","author":"Zak","year":"2013","journal-title":"J Med Chem"},{"key":"R30-21-20210128","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.","volume":"13","author":"Chang","year":"2011","journal-title":"Arthr Res Ther"},{"key":"R31-21-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat Chem Biol"},{"key":"R32-21-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.111.181545","article-title":"Antiarthritis effect of a novel Brutons tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokineticpharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.","volume":"338","author":"Liu","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R33-21-20210128","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI42856","article-title":"Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice.","volume":"120","author":"Biswas","year":"2010","journal-title":"J Clin Investig"},{"key":"R34-21-20210128","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0961203312436862","article-title":"Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZBW F1 female mice.","volume":"21","author":"Stirzaker","year":"2012","journal-title":"Lupus"},{"key":"R35-21-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/emboj\/20.1.91","article-title":"Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression.","volume":"20","author":"Kovarik","year":"2001","journal-title":"EMBO J"},{"key":"R36-21-20210128","doi-asserted-by":"crossref","first-page":"12281","DOI":"10.1073\/pnas.182618999","article-title":"STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation.","volume":"99","author":"Morinobu","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R37-21-20210128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1128\/MCB.24.1.407-419.2004","article-title":"Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation.","volume":"24","author":"Shen","year":"2004","journal-title":"Molec Cell Biol"},{"key":"R38-21-20210128","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-7613(03)00322-4","article-title":"Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity.","volume":"19","author":"Varinou","year":"2003","journal-title":"Immunity"},{"key":"R39-21-20210128","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2009-12-258913","article-title":"Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.","volume":"116","author":"Friedbichler","year":"2010","journal-title":"Blood"},{"key":"R40-21-20210128","doi-asserted-by":"crossref","first-page":"8944","DOI":"10.1073\/pnas.0801794105","article-title":"Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain.","volume":"105","author":"Sadzak","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R41-21-20210128","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.immuni.2012.10.017","article-title":"CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response.","volume":"38","author":"Bancerek","year":"2013","journal-title":"Immunity"},{"key":"R42-21-20210128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbrc.2013.04.096","article-title":"CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice.","volume":"435","author":"Yoshida","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"R43-21-20210128","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1038\/cddis.2012.64","article-title":"A novel role for RIP1 kinase in mediating TNFalpha production.","volume":"3","author":"Christofferson","year":"2012","journal-title":"Cell Death Dis"},{"key":"R44-21-20210128","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12174","article-title":"RIP1-driven autoinflammation targets IL-1alpha independently of inflammasomes and RIP3.","volume":"498","author":"Lukens","year":"2013","journal-title":"Nature"},{"key":"R45-21-20210128","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2009-07-232330","article-title":"PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.","volume":"115","author":"Soond","year":"2010","journal-title":"Blood"},{"key":"R46-21-20210128","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/08916934.2012.732130","article-title":"Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in nonobese diabetic (NOD) mice.","volume":"46","author":"Durand","year":"2013","journal-title":"Autoimmunity"},{"key":"R47-21-20210128","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:31:34Z","timestamp":1620948694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201403000-00021"}},"subtitle":["treating rheumatic diseases and beyond"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000023","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}